Boston (September 11, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to…
Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation…
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of…
BOSTON, Sept. 10, 2024 /PRNewswire/ -- AG Mednet, the pioneering force in clinical trial process management, continues to experience rapid…
Expanding Impact to Connect Healthcare Companies and Their Most Important Audiences PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Health Union, the…
CLEVELAND, Sept. 10, 2024 /PRNewswire/ -- September 4th, 2024. GenomOncology, a leading provider of precision medicine software, and Precipio, a…
SAN ANTONIO, Sept. 10, 2024 /PRNewswire/ -- RealTime eClinical Solutions, a leader in clinical trial technology, proudly announces its continued…
New tech-enabled services empower pharmaceutical companies to optimize biospecimen operations and data management, transforming sample data into actionable insights RICHMOND,…
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully…
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the…